Ketamine for treatment-resistant unipolar depression: current evidence - Wikidata - awgldk - TriplyDB

Ketamine for treatment-resistant unipolar depression: current evidence

Ketamine for treatment-resistant unipolar depression: current evidence

http://www.wikidata.org/entity/Q27004508

about

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults Ketamine and other glutamate receptor modulators for depression in adults Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice Therapeutic infusions of ketamine: do the psychoactive effects matter?The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.A randomized controlled trial of intranasal ketamine in major depressive disorder.Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.NMDA receptor antagonist ketamine impairs feature integration in visual perception Further evidence of emotional allodynia in unmedicated young adults with major depressive disorder GPR39 (zinc receptor) knockout mice exhibit depression-like behavior and CREB/BDNF down-regulation in the hippocampus PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13.Does ketamine have anti-suicidal properties? Current status and future directions Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.Differential Efficacy of Ketamine in the Acute versus Chronic Stages of Complex Regional Pain Syndrome in Mice Understanding resilience.Ketamine, Propofol, and the EEG: A Neural Field Analysis of HCN1-Mediated Interactions.New Hippocampal Neurons Mature Rapidly in Response to Ketamine But Are Not Required for Its Acute Antidepressant Effects on Neophagia in Rats.Repeated administration of imipramine modifies GABAergic transmission in rat frontal cortex.Is there anything really novel on the antidepressant horizon?Effect of Ketamine, Thiopental and Ketamine-Thiopental Combination during Electroconvulsive Therapy for Depression.Current status of ketamine and related compounds for depression Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects.A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.The promise of ketamine for treatment-resistant depression: current evidence and future directions.Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review.New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators.Ketamine for treatment-resistant depression: recent developments and clinical applications.Kinase-mediated signaling cascades in mood disorders and antidepressant treatment.Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression

P2860

Q21129276-3B5E56EF-2770-4660-8605-358111EC041F Q22252957-EA93161B-A3FC-4DFE-886C-CAD96C891C88 Q24186726-0485D168-ECCB-475D-AFA8-4A4401CB5FC7 Q24186746-A0C43D90-D021-41A9-875D-751B0E492E95 Q27004490-BF5C8853-338F-411D-9DC1-568055467A37 Q28485938-88547E47-04B1-4D7D-84FA-F71900CEA4EC Q33880853-FF52FC8F-35B3-415A-B0B8-C6B595C17462 Q33926787-BEBBC700-D1DC-452A-B064-9B65347D54C7 Q34288196-13515BFF-D05D-4031-B1BA-92EDE074A384 Q34475595-15266854-FA40-4171-928E-DB5D9B8F5D57 Q34655680-223C6451-D470-4E02-A87F-EA11C7BE88F9 Q35041262-5FA28BA8-F415-4EC0-B085-1FCEA2355505 Q35060326-F10A6B27-48A0-4714-B5C1-394F3BFFD736 Q35179047-D22074C9-88F1-4602-A1A7-0CE226C82690 Q35224315-6BB59691-BED6-4BE0-865F-F3E8A0ABBE5B Q35235620-A95A0901-260A-4BA9-91B9-F47A8DC739B7 Q35894579-6FE68075-45CD-46DE-95A5-0933C70B0CF8 Q36372728-14B6E3B9-CCEE-4E52-8E74-8B0C1FAEBBC9 Q36612228-FB481366-A57E-41F2-A6C4-4EF0A3B8E0E3 Q36743155-3806C5C6-9966-4D63-9F18-4831D02DB114 Q36760914-07961725-02CB-4767-B73B-7269450D842C Q36781548-7189CC24-B652-42B5-B357-5AEA66BDE6AE Q36870889-C0D81814-FED7-4019-B143-3EBD6C1A5F79 Q36972133-E4ACB6AC-5622-4656-90A8-A2C59B73F66B Q37202885-4EB1D5F8-91CF-4E21-A529-D66CC7E03958 Q37279054-A81BC78F-5DF0-4F6F-A230-7D0694701164 Q37424333-E6ACE44E-0970-4B3B-AAD9-D683A508D718 Q37634301-9AA68345-A105-4C25-91E3-13FD6001956B Q37668014-E20495B3-678D-46BD-AF61-F4FA169EB4BB Q37709284-CE98AF27-8E88-4025-B2EA-854A86F68412 Q37712452-8D04E54C-6957-4052-A03C-2D3C2CA6478E Q38049302-AF0A52C2-323F-49FE-9B56-3458BBAD8CAB Q38227967-93995F33-8234-427D-9324-07CF90C610E9 Q38343315-10B1279B-7CF2-4C9F-87A0-BC271440794F Q38633125-186CFF24-5D75-4DE8-998A-7B4569CC8FFA Q38685420-96C68B74-3343-4B97-A94C-1114A2E07033 Q38705814-0505E48C-124C-4386-A7B3-9646043D3444 Q38800172-E0FE3E50-B2E9-4039-9454-FA0F63033B1A Q38804430-C8C3AB65-DC13-451B-AB3E-A432C4759AA5 Q38990885-FDB2F44D-7374-4924-B633-C669A2D5AE0F

P2860

Ketamine for treatment-resistant unipolar depression: current evidence

http://www.wikidata.org/entity/Q27004508

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Ketamine for treatment-resistant unipolar depression: current evidence

@ast

Ketamine for treatment-resistant unipolar depression: current evidence

@en

Ketamine for treatment-resistant unipolar depression: current evidence

@nl

type

label

Ketamine for treatment-resistant unipolar depression: current evidence

@ast

Ketamine for treatment-resistant unipolar depression: current evidence

@en

Ketamine for treatment-resistant unipolar depression: current evidence

@nl

prefLabel

Ketamine for treatment-resistant unipolar depression: current evidence

@ast

Ketamine for treatment-resistant unipolar depression: current evidence

@en

Ketamine for treatment-resistant unipolar depression: current evidence

@nl

P1433

Q27004508-41F3F723-4323-4E1F-ADD8-02CC607CAB50

P1476

Q27004508-8A442D02-0750-488F-B6FA-415B2DCC43B6

P2093

Q27004508-7AF5E16B-DB35-44C3-AA28-1F08095B5010

Q27004508-8444FBE7-9BEC-40F3-86E1-5264A0BFB4B5

Q27004508-99862BE3-813D-4250-A7A1-021B69D33711

Q27004508-DCD6695C-8AC7-4FEF-8CB8-16A7BE4316DD

Q27004508-DDCEB306-E17B-45E4-8639-92C37639ABD3

Q27004508-F3BEF68A-1D9B-4F64-94DF-F22926CD98B8

Q27004508-FACA341D-5576-4157-997B-21050ADF33AE

P2860

Q27004508-005551AD-DDD9-4BBA-8468-0FB41FFF4687

Q27004508-0104C8D3-9AEE-479D-AB0A-5452F6515216

Q27004508-03BA4681-7813-4498-B96C-DD01EFCAA9AF

Q27004508-0546E7CA-14C5-4AB4-9454-595FB831C656

Q27004508-05A48BA6-C822-4606-A30B-D5FD15AA0BFB

Q27004508-0C66FE30-1FC6-48D7-8544-152596D777D6

Q27004508-0E757AE4-C01D-407E-B579-EA93C703348F

Q27004508-12921E4C-8083-4D13-BB2E-B49566D9D5D2

Q27004508-16A51641-D416-45CF-A091-D945A8EA3354

Q27004508-16C8959E-FECA-4289-AB3D-11B25842D6BD

P2888

Q27004508-595EF502-69BC-403F-8428-E12B95ED43A9

P304

Q27004508-EE138B19-C939-46CC-9F52-3C71C95BE5AE

P31

Q27004508-A4C04EB7-9229-48AB-8896-EB8B7769E844

P3181

Q27004508-76E0F193-5686-4470-BF02-72BD0040E1BA

P356

Q27004508-F0671D74-75B1-4CD2-BA5D-A0E63DCADD60

P407

Q27004508-BA151B8B-0C4D-4F16-BC03-245638818932

P433

Q27004508-F64F5DED-ED18-4EC2-967A-3625F72CE71D

P478

Q27004508-22D95BDA-2E43-4C91-8A9B-AF34F66A1026

P577

Q27004508-260F4230-567A-43BB-B833-6195B67FC089

P5875

Q27004508-59731058-8760-43D3-93D2-EE465F4D7D53

P6179

Q27004508-49D2A11E-B71A-473A-B26B-58AD3685ED87

P698

Q27004508-1D8FAF5D-7CDC-4897-94CF-FD38BA826FC9

P932

Q27004508-C2911360-A5E8-4CB1-89EF-5E0DAF31514E

P3181

P356

11599770-000000000-00000

P1433

P1476

Ketamine for treatment-resistant unipolar depression: current evidence

@en

P2093

Asim Shah

http://www.w3.org/2001/XMLSchema#string

Britta Ostermeyer

http://www.w3.org/2001/XMLSchema#string

Crystal Clark

http://www.w3.org/2001/XMLSchema#string

James W. Murrough

http://www.w3.org/2001/XMLSchema#string

Kyle Lapidus

http://www.w3.org/2001/XMLSchema#string

Noor Jarun

http://www.w3.org/2001/XMLSchema#string

Sanjay J. Mathew

http://www.w3.org/2001/XMLSchema#string

P2860

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine.

Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons

Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex

Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later

Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study

NMDA antagonist neurotoxicity: mechanism and prevention

The clinical use of S-(+)-ketamine--a determination of its place

P2888

11599770-000000000-00000

P304

189-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4964700

http://www.w3.org/2001/XMLSchema#string

P356

10.2165/11599770-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221804547

http://www.w3.org/2001/XMLSchema#string

P6179

1001769981

http://www.w3.org/2001/XMLSchema#string

P698

22303887

http://www.w3.org/2001/XMLSchema#string

P932

3677048

http://www.w3.org/2001/XMLSchema#string